Our results indicated that overexpression of SPRY1 protein is potentially associated with human oral squamous cell carcinogenesis.
Our results indicated that overexpression of SPRY1 protein is potentially associated with human oral squamous cell carcinogenesis.There are few studies comparing the expression of enamel proteins, such as amelogenin, and cytokeratins in cyst and odontogenic tumors like in ameloblastoma and odontogenic keratocyst, indicating that amelogenin could be a potential biomarker for the aggressiveness in the odontogenic tumors. The aim of this study was to evaluate if the expression of amelogenin, cytokeratin AE1/AE3 (CKAE1/AE3) and cytokeratin 14 (CK14) in cysts and odontogenic tumors with calcified matrices such as calcifying odontogenic cyst (COC), compound (CdO) and complex (CxO) odontomas, adenomatoid odontogenic tumor (AOT) and calcifying epithelial odontogenic tumor (CEOT) as an aggressiveness indicator.
Three COC, eight CxO, three CdO, twelve AOT, two CEOT and three dental germs were submitted to an immunohistochemistry panel of antibodies composed of amelogenin, CKAE1/AE3 and CK14.
CKAE1/AE3 and CK14 was present in all odontogenic epithelia. The amelogenin protein was detected in prismatic and amorphous calcified matrices of epithelial origin belonging to CxO, CdO, AOT, COC and the tooth germs used as controls. On the other hand, the CEOT was the only tumor or cyst studied that did not present immunostaining for amelogenin in calcified matrices.
Amelogenin was detected in pathologies with a low or absent recurrence rate and excellent prognosis. CEOT was the lesion of greater clinical aggressiveness which did not express amelogenin. The presence of amelogenin in calcified matrices of odontogenic arise could be an indicator of low aggressiveness.
Amelogenin was detected in pathologies with a low or absent recurrence rate and excellent prognosis. CEOT was the lesion of greater clinical aggressiveness which did not express amelogenin. The presence of amelogenin in calcified matrices of odontogenic arise could be an indicator of low aggressiveness.The early diagnosis of diabetes is essential for the prevention of complications. Periodontitis has been identified as the sixth complication of diabetes and chair-side screening may improve diagnosis of diabetes. This study evaluated whether gingival crevicular blood (GCB) available during routine periodontal examination can be used to screen for diabetes in Chinese patients with moderate to severe periodontitis.
Finger-stick blood (FSB) and GCB were collected from patients (18 with diabetes and 42 without diabetes) during routine periodontal probing and analyzed for glucose and hemoglobin A1c (HbA1c) levels.
In the diabetic group, the mean glucose levels in GCB and FSB were 12.21?±?3.86 and 12.61?±?4.19?mmol/L respectively, while those of the non-diabetic group were 6.14?±?0.85 and 6.15?±?0.87?mmol/L, respectively. https://www.selleckchem.com/products/go-203.html The average HbA1c values of the diabetic group were 7.72%?±?1.71% and 7.89%?±?1.78% in GCB and FSB, respectively, while those of the non-diabetic group were 5.28%?±?0.31% and 5.23%?±?0.32%, respectively. Highly significant correlations were found between GCB and FSB glucose levels (r?=?0.993 for the diabetic group, and r?=?0.977 for the non-diabetic group) and between GCB and FSB HbA1c levels (r?=?0.977 for the diabetic group, and r?=?0.829 for the non-diabetic group).
Our study results indicate that GCB available during routine periodontal examination may be acceptable for the analyses of blood glucose and HbA1c levels. The approach is suitable for screening undiagnosed diabetes in a dental setting.
Our study results indicate that GCB available during routine periodontal examination may be acceptable for the analyses of blood glucose and HbA1c levels. The approach is suitable for screening undiagnosed diabetes in a dental setting.Multiple studies demonstrate that fluctuating blood glucose level produces greater damage compared with sustained hyperglycemia. Flash glucose monitoring system is an effective method in documenting blood glucose variability, contributing to better glucose management and reduced hypoglycemic event occurrence.
To investigate the improvement in glycemic variability (GV), blood glucose level, and metabolic indexes of patients with type 2 diabetes mellitus after combined treatment of exenatide once weekly (EXQW) and metformin.
Twenty-five patients with type 2 diabetes mellitus suffering from poor blood glucose control under metformin treatment were recruited. The recruited patients were prescribed with oral metformin only (maintaining a dosage of metformin at ? 1500 mg/day) for 2 wk (screening period), and then given EXQW (2 mg, subcutaneous injection) for 12 wk (experimental period). The flash glucose monitoring system was used to document blood glucose values during the screening period and the last 2 wk ods significantly increased after treatment (= 0.041 and 0.028, respectively), but there was no significant increase in severe hypoglycemia (&lt; 3.0 mmol/L) compared with that at baseline (= 0.207). In addition, some metabolic indicators improved after EXQW treatment.
EXQW combined with metformin can effectively improve blood glucose levels, reduce GV, and improve metabolic indicators. However, there is still a risk of nocturnal hypoglycemia, and careful attention should be paid to patients with EXQW treatment.
EXQW combined with metformin can effectively improve blood glucose levels, reduce GV, and improve metabolic indicators. However, there is still a risk of nocturnal hypoglycemia, and careful attention should be paid to patients with EXQW treatment.Coronavirus disease 2019 (COVID-19) is a pandemic disease spreading all over the world and has aroused global concerns. The increasing mortality has revealed its severity. It is important to distinguish severe patients and provide appropriate treatment and care to prevent damages. Diabetes is reported to be a common comorbidity in COVID-19 patients and associated with higher mortality. We attempted to clarify the relationship between diabetes and COVID-19 patients' severity.
To determine the role of type 2 diabetes in COVID-19 patients.
To study the relationship between diabetes and COVID-19, we retrospectively collected 61 patients' data from a tertiary medical center in Wuhan. All the patients were diagnosed with laboratory-confirmed COVID-19 and admitted to the center from February 13 to March 1, 2020. Patients' age, sex, laboratory tests, chest computed tomography findings, capillary blood glucose (BG), and treatments were collected and analyzed. Fisher exact test was used for categorical data. Univariate and multivariate logistic regressions were used to explore the relationship between clinical characteristics and patients' severity.